OncoCyte Analyst Ratings
OncoCyte Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | 3.55% | Piper Sandler | $6 → $3.5 | Maintains | Neutral |
| 08/10/2023 | 25.74% | Needham | $9 → $4.25 | Maintains | Buy |
| 04/04/2023 | -86.69% | Needham | $1.4 → $0.45 | Maintains | Buy |
| 12/01/2022 | -85.21% | Lake Street | $3 → $0.5 | Downgrades | Buy → Hold |
| 11/18/2022 | -85.21% | Piper Sandler | $1 → $0.5 | Downgrades | Overweight → Neutral |
| 11/14/2022 | -70.41% | Piper Sandler | $1.5 → $1 | Maintains | Overweight |
| 11/11/2022 | -58.58% | Needham | $2.1 → $1.4 | Maintains | Buy |
| 08/17/2022 | -55.62% | Piper Sandler | $1.4 → $1.5 | Maintains | Overweight |
| 08/11/2022 | -11.24% | Lake Street | $6 → $3 | Maintains | Buy |
| 08/11/2022 | -37.87% | Needham | $2.25 → $2.1 | Maintains | Buy |
| 05/24/2022 | — | Stephens & Co. | Downgrades | Overweight → Equal-Weight | |
| 05/16/2022 | -58.58% | Piper Sandler | $1.8 → $1.4 | Maintains | Overweight |
| 05/12/2022 | -33.43% | Needham | $4 → $2.25 | Maintains | Buy |
| 03/18/2022 | -46.75% | Piper Sandler | $3.1 → $1.8 | Maintains | Overweight |
| 03/14/2022 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
| 03/11/2022 | 77.51% | Lake Street | $11 → $6 | Maintains | Buy |
| 03/11/2022 | 18.34% | Needham | $5 → $4 | Maintains | Buy |
| 01/07/2022 | -8.28% | Stephens & Co. | → $3.1 | Initiates Coverage On | → Overweight |
| 12/16/2021 | 47.93% | Needham | $7 → $5 | Maintains | Buy |
| 11/10/2021 | 107.1% | Needham | $8 → $7 | Maintains | Buy |
| 03/17/2021 | 136.69% | Needham | → $8 | Assumes | → Buy |
| 12/16/2020 | 18.34% | Piper Sandler | $2 → $4 | Upgrades | Neutral → Overweight |
| 11/30/2020 | 47.93% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 11/13/2020 | 18.34% | Needham | $2 → $4 | Maintains | Buy |
| 11/10/2020 | 47.93% | Keybanc | → $5 | Initiates Coverage On | → Overweight |
| 07/30/2020 | 77.51% | Benchmark | $7 → $6 | Maintains | Speculative Buy |
| 07/01/2020 | -40.83% | Needham | $4 → $2 | Maintains | Buy |
| 06/30/2020 | -40.83% | Chardan Capital | $7.75 → $2 | Downgrades | Buy → Neutral |
| 06/02/2020 | 18.34% | Needham | → $4 | Initiates Coverage On | → Buy |
| 02/13/2019 | 77.51% | Piper Sandler | → $6 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月15日 | 3.55% | 派珀·桑德勒 | $6→$3.5 | 維護 | 中性 |
| 2023年08月10日 | 25.74% | 李約瑟 | $9→$4.25 | 維護 | 買 |
| 04/04/2023 | -86.69% | 李約瑟 | $1.4→$0.45 | 維護 | 買 |
| 12/01/2022 | -85.21% | 萊克街 | $3→$0.5 | 評級下調 | 購買→Hold |
| 2022年11月18日 | -85.21% | 派珀·桑德勒 | $1→$0.5 | 評級下調 | 超重→中性 |
| 2022年11月14日 | -70.41% | 派珀·桑德勒 | $1.5→$1 | 維護 | 超重 |
| 2022年11月11日 | -58.58% | 李約瑟 | $2.1→$1.4 | 維護 | 買 |
| 2022/08/17 | -55.62% | 派珀·桑德勒 | $1.4→$1.5 | 維護 | 超重 |
| 2022年08月11日 | -11.24% | 萊克街 | $6→$3 | 維護 | 買 |
| 2022年08月11日 | -37.87% | 李約瑟 | $2.25→$2.1 | 維護 | 買 |
| 2022年05月24日 | - | 斯蒂芬斯公司 | 評級下調 | 超重→等重 | |
| 05/16/2022 | -58.58% | 派珀·桑德勒 | $1.8→$1.4 | 維護 | 超重 |
| 2022年05月12日 | -33.43% | 李約瑟 | $4→$2.25 | 維護 | 買 |
| 03/18/2022 | -46.75% | 派珀·桑德勒 | $3.1→$1.8 | 維護 | 超重 |
| 03/14/2022 | - | KeyBanc | 評級下調 | 增持→板塊權重 | |
| 03/11/2022 | 77.51% | 萊克街 | $11→$6 | 維護 | 買 |
| 03/11/2022 | 18.34% | 李約瑟 | $5→$4 | 維護 | 買 |
| 01/07/2022 | -8.28% | 斯蒂芬斯公司 | →$3.1 | 開始承保 | →超重 |
| 12/16/2021 | 47.93% | 李約瑟 | $7→$5 | 維護 | 買 |
| 2021年11月10日 | 107.1% | 李約瑟 | $8→$7 | 維護 | 買 |
| 03/17/2021 | 136.69% | 李約瑟 | →$8 | 假設 | →購買 |
| 12/16/2020 | 18.34% | 派珀·桑德勒 | $2→$4 | 升級 | 中性→超重 |
| 11/30/2020 | 47.93% | BTIG | →$5 | 開始承保 | →購買 |
| 11/13/2020 | 18.34% | 李約瑟 | $2→$4 | 維護 | 買 |
| 11/10/2020 | 47.93% | KeyBanc | →$5 | 開始承保 | →超重 |
| 07/30/2020 | 77.51% | 基準 | $7→$6 | 維護 | 投機性購買 |
| 07/01/2020 | -40.83% | 李約瑟 | $4→$2 | 維護 | 買 |
| 06/30/2020 | -40.83% | 查爾丹資本 | $7.75→$2 | 評級下調 | 購買→中性 |
| 06/02/2020 | 18.34% | 李約瑟 | →$4 | 開始承保 | →購買 |
| 2019年02月13日 | 77.51% | 派珀·桑德勒 | →$6 | 開始承保 | →超重 |
What is the target price for OncoCyte (OCX)?
OCX的目標價是多少？
The latest price target for OncoCyte (NASDAQ: OCX) was reported by Piper Sandler on August 15, 2023. The analyst firm set a price target for $3.50 expecting OCX to rise to within 12 months (a possible 3.55% upside). 8 analyst firms have reported ratings in the last year.
派珀·桑德勒於2023年8月15日報道了OncoCyte(納斯達克：OCX)的最新目標價。這家分析公司將目標價定為3.50美元，預計OCX將在12個月內上漲至3.55%(可能上漲3.55%)。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for OncoCyte (OCX)?
分析師對OCX的最新評級是多少？
The latest analyst rating for OncoCyte (NASDAQ: OCX) was provided by Piper Sandler, and OncoCyte maintained their neutral rating.
分析師對OncoCyte(納斯達克代碼：OCX)的最新評級由Piper Sandler提供，OncoCyte維持中性評級。
When is the next analyst rating going to be posted or updated for OncoCyte (OCX)?
OncoCyte(OCX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of OncoCyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for OncoCyte was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與OncoCyte的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。OncoCyte的上一次評級是在2023年8月15日提交的，所以你應該預計下一次評級將在2024年8月15日左右的某個時候公佈。
Is the Analyst Rating OncoCyte (OCX) correct?
分析師對OncoCyte(OCX)的評級正確嗎？
While ratings are subjective and will change, the latest OncoCyte (OCX) rating was a maintained with a price target of $6.00 to $3.50. The current price OncoCyte (OCX) is trading at is $3.38, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的OncoCyte(OCX)評級維持不變，目標價在6.00美元至3.50美元之間。目前OncoCyte(OCX)的交易價格為3.38美元，超出了分析師的預測區間。